Short Interest in Daxor Co. (NASDAQ:DXR) Increases By 7.1%

Daxor Co. (NASDAQ:DXR) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 9,000 shares, an increase of 7.1% from the December 31st total of 8,400 shares. Based on an average trading volume of 16,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.5% of the shares of the company are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its position in Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.34% of the company’s stock.

Daxor Stock Performance

Daxor stock traded up $0.07 during midday trading on Tuesday, reaching $7.85. 6,860 shares of the stock were exchanged, compared to its average volume of 5,256. Daxor has a 52 week low of $7.19 and a 52 week high of $10.00. The company’s fifty day moving average is $8.33 and its 200-day moving average is $8.73.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.